Jeff Ross

647 total citations
22 papers, 476 citations indexed

About

Jeff Ross is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Jeff Ross has authored 22 papers receiving a total of 476 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Cancer Research and 9 papers in Oncology. Recurrent topics in Jeff Ross's work include Cancer Genomics and Diagnostics (7 papers), Cancer Mechanisms and Therapy (3 papers) and Lung Cancer Research Studies (3 papers). Jeff Ross is often cited by papers focused on Cancer Genomics and Diagnostics (7 papers), Cancer Mechanisms and Therapy (3 papers) and Lung Cancer Research Studies (3 papers). Jeff Ross collaborates with scholars based in United States, Spain and Czechia. Jeff Ross's co-authors include Christine E. Sheehan, Shridevi Karikehalli, Norio Azumi, Bhaskar Kallakury, Keith E. Kortman, John P. Karis, Russell L. Anderson, Joseph E. Heiserman, Neil R. Crawford and Bruce L. Dean and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Jeff Ross

21 papers receiving 466 citations

Peers

Countries citing papers authored by Jeff Ross

Since Specialization

Citations

This map shows the geographic impact of Jeff Ross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeff Ross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeff Ross more than expected).

Fields of papers citing papers by Jeff Ross

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeff Ross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeff Ross. The network helps show where Jeff Ross may publish in the future.

Co-authorship network of co-authors of Jeff Ross

This figure shows the co-authorship network connecting the top 25 collaborators of Jeff Ross. A scholar is included among the top collaborators of Jeff Ross based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeff Ross. Jeff Ross is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases 2025 ·Annals of Oncology ·James A. Wilcox, (unknown), (unknown), (unknown), (unknown), Glenn Heller, Noura J. Choudhury, Jeff Ross, Charles M. Rudin, Gregory J. Riely, Mark G. Kris, Mark T.A. Donoghue, Adrienne Boire, Helena A. Yu	0
2	ERBB2‐amplified lobular breast carcinoma exhibits concomitant CDK12 co‐amplification associated with poor prognostic features 2024 ·The Journal of Pathology Clinical Research ·(unknown), Martin Zoche, Bernhard C. Pestalozzi, Isabell Witzel, Esther I. Schwarz, (unknown), Hisham Fansa, Christoph Tausch, Jeff Ross, Holger Moch, Zsuzsanna Varga	3
3	Abstract 2337: Pan-cancer analysis of sex differences and their associations with ancestry and genomic biomarkers in a large comprehensive genomic profiling dataset 2020 ·Cancer Research ·(unknown), (unknown), Justin Y. Newberg, Ethan S. Sokol, Meagan Montesion, Lee A. Albacker, Vincent Miller, Jeff Ross, Garrett M. Frampton, (unknown)	1
4	80 Smarca4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association 2019 ·Douglas I. Lin, Jason D. Allen, Jonathan L. Hecht, J. Keith Killian, Nye Thane Ngo, Claire Edgerly, Eric A. Severson, Siraj M. Ali, Rachel Erlich, Shakti Ramkissoon, (unknown), Jeff Ross, Julia A. Elvin	2
5	Pan-cancer analysis of clinical acquired resistance (AR) in BRAF-driven real-world cases 2019 ·Annals of Oncology ·Filippo Pietrantonio, (unknown), (unknown), Carolina Schinke, Gordan Srkalović, Russell W. Madison, Jeff Ross, V.A. Miller, Brian M. Alexander, Sonia Ali, Alexa B. Schrock, Garrett Daniels	1
6	Immune checkpoint inhibitor (ICPI) efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC) 2017 ·Annals of Oncology ·Jeff Ross, Michael E. Goldberg, Lee A. Albacker, Laurie M. Gay, Vineeta Agarwala, Julia A. Elvin, (unknown), John H. Suh, (unknown), Eric A. Severson, (unknown), Siraj M. Ali, Alexa B. Schrock, Garrett M. Frampton, David Fabrizio, V.A. Miller, Gaurav Singal, Amy P. Abernethy, (unknown)	8
7	MA 07.07 Clinical Outcomes and ALK Resistance Mutations in ALK+ Non-Small Cell Lung Cancer According to EML4-ALK Variant 2017 ·Journal of Thoracic Oncology ·W. Marston Linehan, Viola W. Zhu, Satoshi Yoda, B.Y. Yeap, Nicholas A. Jessop, (unknown), Ibiayi Dagogo‐Jack, Kyle Gowen, (unknown), Jeff Ross, Saima Ali, Virginia L. Miller, Justin F. Gainor, Aaron N. Hata, A. John Iafrate, (unknown), Alice T. Shaw	2
8	Comprehensive Genomic Profiling of Uterine Leiomyosarcomas Identifies Frequent Clinically Relevant Genomic Alterations and Opportunities for Personalized Therapies 2016 ·Gynecologic Oncology ·Camille C. Gunderson, Alessandro D. Santin, (unknown), (unknown), Shakti Ramkissoon, Shujath M. Ali, (unknown), David Fabrizio, Zachary R. Chalmers, Garrett M. Frampton, Juliann Chmielecki, Jo‐Anne Vergilio, (unknown), Laurie M. Gay, V.A. Miller, (unknown), Jeff Ross, Kathleen N. Moore	2
9	Comprehensive Clinical Genomic Profiling Defines Age-Associated Molecular Targets in Pediatric and Adult Acute Myeloid Leukemia 2016 ·Blood ·Katherine Tarlock, Shan Zong, (unknown), Mark Bailey, Samantha Morley, Sohail Balasubramanian, Rachel Erlich, Doron Lipson, Geoff Otto, (unknown), Cu Nguyen, (unknown), Daoud Meerzaman, E. Anders Kolb, Jeff Ross, Tariq I. Mughal, Phil Stephens, Vincent A. Miller, Soheil Meshinchi, Jie He	1
10	3007 Comprehensive genomic profiling characterizes the cpectrum of non-V600E activating BRAF alterations Including BRAF fusions in lung cancer 2015 ·European Journal of Cancer ·(unknown), (unknown), (unknown), James Suh, Andreas Heilmann, Doron Lipson, Roman Yelensky, Juliann Chmielecki, Julia A. Elvin, Kartik Konduri, (unknown), Peter Stephens, Jeff Ross, (unknown)	3
11	Vemurafenib Response in 2 Patients With Posttransplant Refractory BRAF V600E–Mutated Multiple Myeloma 2014 ·Clinical Lymphoma Myeloma & Leukemia ·Jeff P. Sharman, Juliann Chmielecki, Deborah Morosini, Gary A. Palmer, Jeff Ross, P. J. Stephens, (unknown), V.A. Miller, Sonia Ali	41
12	Novel Chromatin Modifying Gene Alterations and Significant Survival Association of ATM and P53 in Mantle Cell Lymphoma 2014 ·Blood ·Kai Wang, Michelle Nahas, Roman Yelensky, Geoff Otto, Doron Lipson, Jie He, Jeff Ross, Phil Stephens, Kar Fai Chow, (unknown), Pritish K. Bhattacharyya, (unknown), Tatyana Feldman, Anthony R. Mato, Alan P Skarbnik, (unknown), (unknown), Andrew L. Pecora, Vincent A. Miller, André Goy	2
13	Anatomical and Biomechanical Analyses of the Unique and Consistent Locations of Sacral Insufficiency Fractures 2009 ·Spine ·(unknown), Joseph E. Heiserman, Keith E. Kortman, Neil R. Crawford, Seungwon Baek, Russell L. Anderson, Alan Pitt, John P. Karis, Jeff Ross, Gregory P. Leković, Bruce L. Dean	89
14	Pharmacological inhibition and silencing of classical IKK-NF-κB pathway by siRNA sensitizes cancer cells to doxorubicin 2006 ·Journal of Clinical Oncology ·(unknown), Marta Bosch, Mark Rolfe, Jeff Ross, Pere Gascón, Rosario Perona, Ana Rovira, Joan Albanell	1
15	Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms. Clinicopathologic studies. 2006 ·PubMed ·Leoš Křen, Viktor N. Goncharuk, Zdenka Křenová, (unknown), Markéta Hermanová, Jana Skřičková, Christine E. Sheehan, Jeff Ross	22
16	Measurements of estrogen receptor and reporter genes from microarrays determine receptor status and time to recurrence following adjuvant tamoxifen therapy. 2005 ·Breast Cancer Research and Treatment ·W. Fraser Symmans, Christos Sotiriou, Steve Anderson, Christos Hatzis, Vicente Valero, (unknown), Denis Larsimont, Christine Desmedt, David Gold, Nour Sneige, (unknown), (unknown), Yun Yun Gong, Jeff Ross, Kathryn Hess, Martine Piccart, Adrian L. Harris, G. N. Hortobágyi, Lajos Pusztai	10
17	Multicenter study validates PITX2 DNA methylation for risk prediction in tamoxifen-treated, node-negative breast cancer using paraffin-embedded tumor tissue 2005 ·Journal of Clinical Oncology ·Nadia Harbeck, (unknown), Jeff Ross, (unknown), Glen Kristiansen, (unknown), A. Hartmann, (unknown), Angelo Paradiso, Sabine Maier	5
18	Downregulation of plasma membrane expression/cytoplasmic accumulation of beta-catenin predicts shortened survival in non-small cell lung cancer. A clinicopathologic study of 100 cases. 2003 ·PubMed ·Leoš Křen, Markéta Hermanová, Viktor N. Goncharuk, Paramjeet Kaur, Jeff Ross, Zdeněk Pavlovský, (unknown)	21
19	Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. 2001 ·PubMed ·Bhaskar Kallakury, Shridevi Karikehalli, (unknown), Christine E. Sheehan, Norio Azumi, Jeff Ross	250
20	Role of DNA content determination by image analysis in confirmation of dysplasia in Barrett's esophagus. 1994 ·PubMed ·Abdul H. Khan, Hai X. Bui, (unknown), (unknown), (unknown), (unknown), Jeff Ross	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact